Bloomberg - Michelle Cortez Regeneron Pharmaceuticals Inc. said an extensive investigation into a rare and frightening side effect seen in clusters of patients getting its best-selling drug Eylea has been tied to syringes used to inject the medicine into the eye. The company plans to stop distributing some Eylea kits that contain syringes made from batches that were linked to higher rates of the condition, known as intraocular inflammation. ADMISSION OF GUILT Regeneron disclosed the association between the syringes and the inflammation in a letter sent to doctors and posted on the company’s website on Wednesday, following a report by Bloomberg News last week about an unexplained increase in the side effect.
